| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406160 | INDIVIOR | Sustained release small molecule drug formulation |
Jun, 2026
(2 years from now) | |
| US10058554 | INDIVIOR | Sustained release small molecule drug formulation |
Sep, 2026
(2 years from now) | |
| US9597402 | INDIVIOR | Sustained release small molecule drug formulation |
Sep, 2026
(2 years from now) | |
| US11110093 | INDIVIOR | Sustained release small molecule drug formulation |
Nov, 2026
(2 years from now) | |
| US11013809 | INDIVIOR | Sustained delivery formulations of risperidone compound |
Feb, 2028
(3 years from now) | |
| US10010612 | INDIVIOR | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(3 years from now) | |
| US11712475 | INDIVIOR | Sustained delivery formulations of risperidone compound |
Feb, 2028
(3 years from now) | |
| US10376590 | INDIVIOR | Sustained delivery formulations of risperidone compound |
Feb, 2028
(3 years from now) | |
| US9186413 | INDIVIOR | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(3 years from now) | |
| US9180197 | INDIVIOR | Sustained delivery formulations of risperidone compounds |
Feb, 2028
(3 years from now) | |
Perseris Kit is owned by Indivior.
Perseris Kit contains Risperidone.
Perseris Kit has a total of 10 drug patents out of which 0 drug patents have expired.
Perseris Kit was authorised for market use on 27 July, 2018.
Perseris Kit is available in for suspension, extended release;subcutaneous dosage forms.
Perseris Kit can be used as method of treating schizophrenia, treatment of schizophrenia, administration of risperidone, treating schizophrenia.
The generics of Perseris Kit are possible to be released after 13 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2021 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 27 July, 2018
Treatment: Method of treating schizophrenia; Administration of risperidone; Treating schizophrenia; Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
PERSERIS KIT family patents
